tirzepatide molecular structure Tirzepatide Molecule Mounjaro Molecular Structure

packaging verification

Purpose of Review The purpose of this review is two-fold: (1) to discuss a case report of idiopathic intracranial hypertension (IIH) after abrupt cessation of a glucagon-like peptide-1 (GLP-1) receptor agonist with resultant rapid weight gain and (2) to review the literature regarding the potential role of GLP-1 receptor agonists in the treatment of IIH as well as potential pitfalls

GLP-1 plays a key role in appetite regulation, insulin secretion, and gastric emptying, making it a vital hormone for metabolic health

Federal law does not require many compounders to report adverse events to FDA

A new Mayo Clinic study followed 120 postmenopausal women on tirzepatide for 12+ months and found the MHT group lost 19.2% of their body weight compared to 14.0% without MHT

CFU = Colony Forming Units